ABBV AbbVie Inc.
AbbVie Inc. (ABBV) is expected to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is $3.87 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.2% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About AbbVie Inc.
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn' disease, HIV, cystic fibrosis complications.
Sector
Healthcare
Industry
Drug Manufacturers / Major
Held By 9 ETFs, by dollar flow
- XT iShares Exponential Technologies ETF
- OEF iShares S&P 100 ETF
- XLG Invesco S&P 500 Top 50 ETF
- HDV iShares Core High Dividend ETF
- XLV Health Care Select Sector SPDR Fund
- IYH iShares U.S. Healthcare ETF
- IXJ iShares Global Healthcare ETF
- BMED iShares Health Innovation Active ETF
- PPH VanEck Pharmaceutical ETF